Baidu
map

J Clin Oncol:肿瘤化疗期间,究竟该不该补充抗氧化剂?

2020-01-04 QQY MedSci原创

尽管有报道称在癌症治疗期间可广泛使用膳食补充剂,但关于其安全性或有效性的相关数据很少。考虑到一些补充剂,特别是抗氧化剂,可能会降低化疗的细胞毒性,Ambrosone等人开展了一项前瞻性研究以评估补充剂的使用与乳腺癌预后之间的关系。本研究对1134位采用环磷酰胺、阿霉素和紫杉醇化疗的乳腺癌患者在化疗前和化疗过程中补充剂的应用情况进行调查。并对患者入组后6个月的复发率和存活率进行评估。结果显示在治疗前

尽管有报道称在癌症治疗期间可广泛使用膳食补充剂,但关于其安全性或有效性的相关数据很少。考虑到一些补充剂,特别是抗氧化剂,可能会降低化疗的细胞毒性,Ambrosone等人开展了一项前瞻性研究以评估补充剂的使用与乳腺癌预后之间的关系。

本研究对1134位采用环磷酰胺、阿霉素和紫杉醇化疗的乳腺癌患者在化疗前和化疗过程中补充剂的应用情况进行调查。并对患者入组后6个月的复发率和存活率进行评估。

结果显示在治疗前和治疗过程中使用任何抗氧化剂补充剂(维生素A、C和E,类胡萝卜素,辅酶Q10)均与复发风险增加有关(校正风险比[adjHR]1.41,95% CI 0.98-2.04,P=0.06),而且,在一定程度上,还与患者死亡风险增加有关(adjHR 1.40,95% CI 0.90-2.18,P=0.14)。与单个抗氧化剂的关系较弱,可能是因为数量较少。对于非抗氧化剂(维生素B12),在化疗前或化疗中使用与无病存活期(adjHR 1.83,95% CI 1.15-2.92,P<0.01)和总体存活期较短显著相关(adjHR 2.04,95% CI 1.22-3.40,P<0.01)。在化疗期间补充铁剂与复发显著相关(1.79,1.20-2.67,P<0.01)。总体存活期的结果相似。多种维生素应用与存活预后无关。

在化疗前和化疗期间,存活预后与抗氧化剂和其他膳食补充剂应用之间的关系与患者在考虑化疗期间使用补充剂(而不是复合维生素)时的谨慎建议是一致的。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865761, encodeId=82331865e61dd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 27 19:14:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949388, encodeId=b3111949388ea, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Aug 26 22:14:00 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489364, encodeId=283e14893647c, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Jan 06 07:14:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037961, encodeId=b572103e961e5, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Jan 04 19:14:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-03-27 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865761, encodeId=82331865e61dd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 27 19:14:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949388, encodeId=b3111949388ea, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Aug 26 22:14:00 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489364, encodeId=283e14893647c, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Jan 06 07:14:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037961, encodeId=b572103e961e5, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Jan 04 19:14:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865761, encodeId=82331865e61dd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 27 19:14:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949388, encodeId=b3111949388ea, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Aug 26 22:14:00 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489364, encodeId=283e14893647c, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Jan 06 07:14:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037961, encodeId=b572103e961e5, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Jan 04 19:14:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1865761, encodeId=82331865e61dd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Mar 27 19:14:00 CST 2020, time=2020-03-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1949388, encodeId=b3111949388ea, content=<a href='/topic/show?id=50ea6396968' target=_blank style='color:#2F92EE;'>#氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63969, encryptionId=50ea6396968, topicName=氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Wed Aug 26 22:14:00 CST 2020, time=2020-08-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489364, encodeId=283e14893647c, content=<a href='/topic/show?id=9aa7553e366' target=_blank style='color:#2F92EE;'>#抗氧化剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55373, encryptionId=9aa7553e366, topicName=抗氧化剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74938536334, createdName=huanbaofeng, createdTime=Mon Jan 06 07:14:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1037961, encodeId=b572103e961e5, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Jan 04 19:14:00 CST 2020, time=2020-01-04, status=1, ipAttribution=)]
    2020-01-04 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0

Baidu
map
Baidu
map
Baidu
map